MC
NEUP

Merck & Co’s Neuphoria Therapeutics NEUP Stock Holding History

Merck & Co’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$40.8K Hold
10,027
– – 0.01% 13
2025
Q4 		$38.9K Hold
10,027
– – 0.01% 11
2025
Q3 		$118K Hold
10,027
– – 0.05% 12
2025
Q2 		$71.2K Hold
10,027
– – 0.03% 12
2025
Q1 		$57.8K Hold
10,027
– – 0.04% 12
2024
Q4 		$34.4K Buy
+10,027
New +$35.4K 0.01% 13

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.4% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Merck & Co's NEUP Position: Q1 2026 in Review

Merck & Co held its Neuphoria Therapeutics (NEUP) position steady in Q1 2026 at 10,027 shares worth $40.8K. The position accounts for 0.01% of the portfolio, ranked #13.

Merck & Co first reported a position in NEUP in Q4 2024 and has held it in 6 quarters since. The position peaked at $118K in Q3 2025. 19 funds tracked by Wall St. Rank hold NEUP as of Q1 2026.

  • Merck & Co held 10,027 shares of Neuphoria Therapeutics worth $40.8K as of Q1 2026.
  • Merck & Co left its Neuphoria Therapeutics share count unchanged in Q1 2026.
  • Neuphoria Therapeutics made up 0.01% of Merck & Co's portfolio in Q1 2026, its #13 holding.
  • Merck & Co first reported a position in Neuphoria Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • Merck & Co's Neuphoria Therapeutics position peaked at $118K in Q3 2025.
  • 19 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q1 2026.

Based on Merck & Co's 13F filing for Q1 2026, filed 13 May 2026.